CollabRx, Inc. (NASDAQ: CLRX) and Affymetrix, Inc. (NASDAQ: AFFX) said they have announced an agreement to optimize the use of CollabRx´s Genetic Variant Annotation Service in connection with Affymetrix´ OncoScan FFPE Assay Kit and CytoScan Cytogenetics Suite for analysis of gene copy number variation in cancer research.
The overall objective of the partnership is to enable the GVA Service to accept and process gene CNV data directly from OncoScan assays and CytoScan assays to provide scientific knowledge for biomarker CNV profiles in cancer. This powerful informatics solution will pair data from various comprehensive genetic profiling studies, such as somatic mutations from next generation sequencing technologies, with copy number from the OncoScan assay for solid tumors or the CytoScan assay for liquid tumors, and result in a single user friendly report with relevant and dynamically updated knowledge.
CollabRx is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world´s knowledge on genomics-based medicine with specific insights from the nation´s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.
Affymetrix technologies enable multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level, facilitating the rapid translation of bench-top research into clinical and routine use for human health and wellness. For more information about Affymetrix, visit http://www.affymetrix.com.